Teva Pharmaceutical Industries Limited TEVA
Set alert
40.70 USD -1.39 -3.30%
At close
40.33 -0.37 -0.91%
Pre-market · Nov 3, 6:15 AM ET
40.63 Day range 42.00
20.11 52-week range 42.59
- YTD
- +30.41%
- 1 year
- +98.73%
- Open
- 41.12
- Prev close
- 42.09
- Mkt cap
- 47.47B
- Vol
- 10.59M
- Avg vol
- 5.53M
- EPS
- 0.60
- P/E
- 67.83
- Div yield
- 0.00%
More statistics
- Low
- 40.63
- High
- 42.00
- Forward P/E
- 13.18
- Beta
- 0.84
- Short ratio
- 4.40
- Inst. own
- 30.06%
- Dividend
- 0.00
- Ex-div date
- Nov 27, 2017
- Earnings
- Nov 3, 2026
- 50-d avg
- 39.09
- 200-d avg
- 34.58
- 1y target
- 47.58
MAX chart
Events in this range
- Nov 4, 1999Dividend: 0.053
- Nov 7, 2002Dividend: 0.09
- May 5, 2005Dividend: 0.069
- Nov 2, 2007Dividend: 0.101
- Aug 1, 2008Dividend: 0.13
- Nov 7, 2008Dividend: 0.117
- Aug 3, 2009Dividend: 0.154
- Nov 6, 2009Dividend: 0.158
- Aug 2, 2010Dividend: 0.181
- Aug 4, 2011Dividend: 0.235
- Nov 5, 2025Earnings: 0.78; estimate 0.68; surprise 14.71%
- Nov 2, 2026Rating: HC Wainwright & Co. · — → Buy
- Nov 3, 2026Earnings: —; estimate 0.72; surprise —%
Signals (45)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Nov 1, 2025 | 1 year ago |
| SMA: Bullish | May 1, 2024 | 2 years ago |
| SMA: Bullish | Nov 1, 2023 | 3 years ago |
| SMA: Bearish | Feb 1, 2023 | 3 years ago |
| SMA: Bullish | Nov 1, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 1, 2021 | 5 years ago |
| RSI: Oversold | Aug 1, 2017 | 9 years ago |
| SMA: Bearish | Aug 1, 2016 | 10 years ago |
| MACD: Sell Signal | Aug 1, 2016 | 10 years ago |
| SMA: Bearish | Feb 1, 2016 | 10 years ago |
| RSI: Overbought | May 1, 2015 | 11 years ago |
| MACD: Buy Signal | May 1, 2014 | 12 years ago |
| SMA: Bullish | Nov 1, 2013 | 13 years ago |
| SMA: Bullish | Nov 1, 2013 | 13 years ago |
| SMA: Bearish | May 1, 2012 | 14 years ago |
| SMA: Bullish | Nov 1, 2011 | 15 years ago |
| SMA: Bearish | Aug 1, 2011 | 15 years ago |
| SMA: Bearish | Feb 1, 2011 | 15 years ago |
| MACD: Sell Signal | Nov 1, 2010 | 16 years ago |
| RSI: Overbought | Nov 1, 2009 | 17 years ago |
Newest 20 of 45.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.58 +16.9% upside
Now 40.70
- Target (low)
- 42.00
- Target (mean)
- 47.58
- Target (high)
- 55.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy4
- Buy8
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.7302 | 0.60 – 0.89 | 0.00 | 0.0% | 4.24B | -5.3% | 10 |
| Next quarter | 0.75464 | 0.68 – 0.97 | 0.00 | 0.0% | 4.22B | -10.3% | 10 |
| Current year | 2.11 | 1.91 – 2.94 | 0.00 | 0.0% | 16.65B | -3.5% | 13 |
| Next year | 3.09 | 2.86 – 3.35 | 2.11 | +46.6% | 17.23B | +3.5% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Oct 15, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 12, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Oct 1, 2026 | TD Cowen | Initiated | — | Buy |
| Sep 23, 2026 | Oppenheimer | Initiated | — | Outperform |
| Sep 9, 2026 | Leerink Partners | Initiated | — | Outperform |
| Sep 4, 2026 | UBS | Maintained | Buy | Buy |
| Aug 12, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 28, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| May 6, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 30, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 30, 2026 | UBS | Maintained | Buy | Buy |
| Apr 30, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Apr 30, 2026 | Truist Securities | Maintained | Buy | Buy |
| Apr 9, 2026 | B of A Securities | Maintained | Buy | Buy |
| Mar 4, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Feb 18, 2026 | Truist Securities | Maintained | Buy | Buy |
| Feb 9, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Jan 30, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jan 29, 2026 | Scotiabank | Maintained | Sector Outperform | Sector Outperform |
| Jan 29, 2026 | Truist Securities | Maintained | Buy | Buy |
| Jan 6, 2026 | Jefferies | Maintained | Buy | Buy |
| Dec 22, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Dec 19, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 16, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Dec 9, 2025 | B of A Securities | Maintained | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Overweight |
| Dec 8, 2025 | Goldman Sachs | Maintained | Buy | Buy |
| Dec 5, 2025 | Scotiabank | Initiated | — | Sector Outperform |
| Nov 6, 2025 | JP Morgan | Maintained | Overweight | Overweight |
